At iniuva, our foundation is built on a remarkable history of innovation in rare disease treatment. Our founders are not just visionary leaders; they are the very individuals who spearheaded the discovery and development of two pivotal therapies for Phenylketonuria (PKU), a rare genetic disorder.

These highly experienced pioneers initially uncovered the therapeutic effect of BH4 in PKU, meticulously unravelling its complex mode of action. This groundbreaking work directly led to the 2007 approval of Kuvan® 

Not content to rest on their laurels, our founders continued their relentless pursuit of better treatments. They later identified the next-generation drug, sepiapterin, which is now set for crucial EMA/FDA approval in 2025 under PTC Therapeutics as Sephience®.

This extraordinary track record—having already discovered two new therapies for PKU, approved in 2007 and imminently in 2025—demonstrates an unparalleled depth of expertise. It is this unique ability to translate profound scientific understanding from the bedside to breakthrough that defines iniuva. Every day, our team leverages this proven innovation to explore new therapeutic avenues, instilling immense confidence in our capabilities and the vast potential of our company to deliver more life-changing medicines. We are here to bring that same level of dedication and success to future drug development.